Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
7
×
life sciences
national blog main
national top stories
boston
boston blog main
boston top stories
clinical trials
new york blog main
san francisco blog main
startups
atlas venture
deals
gene therapy
new york top stories
regeneron pharmaceuticals
rna interference
san diego blog main
san francisco top stories
adeno-associated virus
akcea therapeutics
alexion pharmaceuticals
allosteric
alnylam pharmaceutials
alnylam pharmaceuticals
amarin
apps
arrowhead pharmaceuticals
astellas pharma
atopic dermatitis
attack
audentes therapeutics
autoimmune disorders
avidity biosciences
barry greene
bio
bluebird bio
boehringer ingelheim
boston university
brace pharma
What
ago
7
×
medicines
therapeutics
years
data
disease
diseases
hearing
long
medical
rare
rna
abandoning
abuzz
adding
address
adds
aiming
allosteric
alnylam
amarin
app
approve
attacks
awaits
baggage
balance
big
biological
biotechs
build
called
caused
chat
clinic
clinical
community
companies
competitor
considering
Language
unset
Current search:
ago
×
biotech
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
4 years ago
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus
@xconomy.com
5 years ago
Deeper Dive: Amarin Fish-Oil Study Gives Eager Doctors More to Ponder
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@techcrunch.com
5 years ago
RDMD attacks rare diseases with data mined from health records
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision